CemiplimAb Survivorship Epidemiology (CASE)

This is a prospective survivorship study of adult patients with Cutaneous Squamous cell Carcinoma (CSCC) who receive treatment with commercially available cemiplimab. The objectives of the study are to identify potential determinants of disease progression, Quality of Life (QOL), and other health-related outcomes. The study also looks to assess patient experience, QOL and functional status, in a real-world setting for patients with CSCC. The information collected from the study will be used to better understand the long-term effectiveness and safety of cemiplimab-rwlc in patients. Cemiplimab-rwlc has been approved by the U.S. FDA for treatment of advanced cutaneous squamous cell carcinoma.

Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital

• Adult male and/or female subjects between the ages of 18 and 70 years receiving treatment with cemiplimab for CSCC, or initiating treatment with cemiplimab for CSCC
• Additional eligibility in protocol

• Patients receiving cemiplimab for an indication other than CSCC
• Additional ineligibility in protocol

For more information go to: https://clinicaltrials.gov/ct2/show/NCT03836105